Get the Stockscreener App
215.40
1.07%
2.28
Pre-market:
214.71
-0.69
-0.32%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $215.40, with a volume of 4.52M.
It is up +1.07% in the last 24 hours and up +9.13% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$213.12
Open:
$213.12
24h Volume:
4.52M
Relative Volume:
0.69
Market Cap:
$380.57B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
106.24
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+1.46%
1M Performance:
+9.13%
6M Performance:
-5.39%
1Y Performance:
+15.98%
1-Day Range:
$211.36
$215.94
1-Week Range:
$209.50
$220.01
52-Week Range:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
215.40 | 376.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,082.92 | 949.47B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.29 | 554.09B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
120.24 | 295.69B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
151.12 | 287.74B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie, Inc. Shs Thailand Depositary Receipts Repr 1 Sh Trade Ideas — SET:ABBV80 - TradingView
US FDA approves AbbVie's rare blood cancer drug - Reuters
AbbVie (ABBV) Receives FDA Approval for Groundbreaking BPDCN Tre - GuruFocus
AbbVie receives FDA approval for BPDCN blood cancer treatment By Investing.com - Investing.com Australia
FDA clears first outpatient BPDCN antibody-drug conjugate for rare blood cancer - Stock Titan
AbbVie (ABBV) Secures FDA Approval for Decnupaz in Rare Blood Ca - GuruFocus
US FDA approves AbbVie’s rare blood cancer drug - WKZO
AbbVie Inc. stock (US00287Y1091): Dividend strength and immunology pipeline in focus - AD HOC NEWS
AbbVie (ABBV) Receives FDA Approval for Decnupaz in Rare Cancer Treatment - GuruFocus
Henri Louw Promoted to Vice President, Business HR – Corporate Staff Functions at AbbVie - hrtoday.in
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds? - TradingView
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. - The Motley Fool
Ironwood, AbbVie win U.S. label expansion for Linzess (IRWD) - Seeking Alpha
Goldman Sachs, Deckers Outdoor And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress - Insider Monkey
Free cash flow of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
Total assets of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Balance Sheet – BCBA:ABBV.CI - TradingView
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Dividends – BCBA:ABBV.CI - TradingView
Price to earnings ratio of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
AbbVie Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
AbbVie (NYSE: ABBV) Form 144: Director proxy to sell $2.78M in shares - Stock Titan
AbbVie Picks North Carolina for Campus - Advanced Manufacturing
Final Trades: AbbVie, Deckers and Goldman Sachs - CNBC
GE Vernova, Estée Lauder, AbbVie: CNBC's 'Final Trades'AbbVie (NYSE:ABBV), Archer-Daniels-Midland (NYS - Benzinga
AbbVie Inc. stock (US00287Y1091): pharma heavyweight between immunology strength and patent reset - AD HOC NEWS
AbbVie Inc. (ABBV) Stock Analysis: Unraveling a 17% Potential Upside Amid Robust Buy Ratings - DirectorsTalk Interviews
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
AbbVie Expands European Reach As Investors Weigh Dividend Support - Yahoo Finance
Hikari Power Ltd's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026 - Yahoo Finance
First Dallas Securities Inc.'s AbbVie Inc(ABBV) Holding History - GuruFocus
Final trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - MSN
KILNER CAPITAL ADVISORS, LLC's AbbVie Inc(ABBV) Holding History - GuruFocus
Final Trades: AbbVie, Millrose Properties, Archer-Daniels-Midland, GE Vernova and Estee Lauder - CNBC
Merck (MRK) and AbbVie (ABBV) Gain EU Panel Endorsements for New Treatments - GuruFocus
AbbVie, Merck, Astra among winners of EU drug recommendations this week - Seeking Alpha
AbbVie (ABBV) Receives Positive EMA Opinion for Maviret Approval - GuruFocus
AbbVie Announces Positive CHMP Opinion for MAVIRET® for the Treatment of Acute Hepatitis C Infection - Investing News Network
AbbVie, Novartis slash US headcount - PharmaLive
AbbVie receives EU panel backing for Maviret in acute hepatitis C - Investing.com Canada
AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection - Yahoo Finance
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market - The Motley Fool
AbbVie to present oncology pipeline data at 2026 ASCO meeting - StreetInsider
Layoff Tracker: AbbVie, Novartis slash US headcount - BioSpace
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline - Investing News Network
AbbVie stock (US00287Y1091): focus on Humira successors after latest quarterly update - AD HOC NEWS
Allergan Aesthetics Receives Positive CHMP Opinion for Boey® for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults - Investing News Network
AbbVie cancer trials show responses in lung, prostate and myeloma - Stock Titan
AbbVie (ABBV) Receives Positive EMA Opinion for Boey Approval - GuruFocus
AbbVie Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.43%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):